Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, February 20, 2017

Cladribine Tablets Reduce Brain Atrophy in MS

Click here to receive MS news via e-mail

EMD Serono has recently published Phase 3 clinical data showing that Cladribine tablets reduced the annualized rate of brain volume loss (BVL, brain atrophy) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS).
CLARITY was a randomized, double-blind, three-arm, placebo-controlled, multi-center Phase 3 clinical trial (NCT00213135) that evaluated the safety and efficacy of oral Cladribine in 1,326 RRMS patients. The primary endpoint was the assessment of the annualized rate of relapse (ARR) at 96 weeks, and key secondary endpoints included the number of relapse-free patients and the sustained progression of disability.

MS Views and News
Providing educational information, resources and services for those affected by MS, globally

No comments: